Проект инициативных клинических рекомендаций по диагностике и лечению поражения почек при АНЦА-ассоциированных васкулитах

1. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715

2. Lyons PA, Rayner TF, Trivedi S et al. Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine. 2012;367(3):214-223. doi:10.1056/NEJMoa1108735

3. Xie G, Roshandel D, Sherva R et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum. 2013;65(9):2457-2468. doi:10.1002/art.38036

4. Tadema H, Abdulahad WH, Lepse N et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford). 2011;50(4):689-696. doi:10.1093/rheumatology/keq375

5. Bienaimé F, Clerbaux G, Plaisier E et al. d-PenicillamineInduced ANCA-Associated Crescentic Glomerulonephritis in Wilson Disease. American Journal of Kidney Diseases. 2007;50(5):821-825. doi:10.1053/j.ajkd.2007.05.026

6. Nolan AL, Jen KY. Pathologic manifestations of levamisole-adulterated cocaine exposure. Diagn Pathol. 2015;10(1). doi:10.1186/s13000-015-0279-z

7. Gómez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. Autoimmun Rev. 2013;12(12):1129-1135. doi:10.1016/j.autrev.2013.06.016

8. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110(7):955-963. doi:10.1172/JCI15918

9. Little MA, Al-Ani B, Ren S et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One. 2012;7(1):e28626. doi:10.1371/journal.pone.0028626

10. Schlieben DJ, Korbet SM, Kimura RE et al. Pulmonaryrenal syndrome in a newborn with placental transmission of ANCAs. American Journal of Kidney Diseases. 2005;45(4):758-761. doi:10.1053/j.ajkd.2005.01.001

11. Kemna MJ, Damoiseaux J, Austen J et al. ANCA as a predictor of relapse: Useful in patients with renal involvement but not in patients with nonrenal disease. Journal of the American Society of Nephrology. 2015;26(3):537-542. doi:10.1681/ASN.2013111233

12. Muller Kobold AC, van der Geld YM, Limburg PC et al. Pathophysiology of ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 1999;14(6):1366-1375. doi: 10.1093/ndt/14.6.1366

13. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115-4119.

14. Radford DJ, Luu NT, Hewins P et al. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum. 2001;44(12):2851-2861. doi: 10.1002/1529-0131(200112)44:12<2851::aid-art473>3.0.co;2-2

15. Kessenbrock K, Krumbholz M, Schönermarck U et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15(6):623-625. doi:10.1038/nm.1959

16. Hilhorst M, Paassen P Van, Rie H Van et al. Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant. 2015;32(8):1302-1313. doi:10.1093/ndt/gfv288

17. Gou SJ, Yuan J, Chen M et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibodyassociated vasculitis. Kidney Int. 2013;83(1):129-137. doi:10.1038/ki.2012.313

18. Gou SJ, Yuan J, Wang C et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clinical Journal of the American Society of Nephrology. 2013;8(11):1884-1891. doi:10.2215/CJN.02790313

19. Jayne DRW, Bruchfeld AN, Harper L et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. Journal of the American Society of Nephrology. 2017;28(9):2756-2767. doi:10.1681/ASN.2016111179

20. Hruskova Z, Rihova Z, Mareckova H et al. Intracellular cytokine production in ANCA-associated vasculitis: low levels of interleukin-10 in remission are associated with a higher relapse rate in the long-term follow-up. Arch Med Res. 2009;40(4):276-284. doi:10.1016/j.arcmed.2009.04.001

21. Lamprecht P, Wieczorek S, Epplen JT et al. Granuloma formation in ANCA-associated vasculitides. APMIS Suppl. 2009;(127):32-36. doi:10.1111/j.1600-0463.2009.02474.x

22. Watts RA, Mahr A, Mohammad AJ et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl1):i14-22. doi:10.1093/ndt/gfv022

23. Berti A, Cornec-Le Gall E, Cornec D et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation. 2019;34(9):1508-1517. doi:10.1093/ndt/gfy250

24. Новиков ПИ, Моисеев СВ, Кузнецова ЕИ и соавт. Изменение клинического течения и прогноза гранулематоза с полиангиитом (Вегенера): результаты 40-летнего наблюдения. Клиническая фармакология и терапия. 2014;23(1):32-37.

25. Томилина НА, Бирюкова ЛС, Фролова и соавт. Клинико-морфологическая характеристика и прогноз разных гистоморфологических вариантов быстропрогрессирующего гломерулонефрита, ассоциированного с АНЦА-васкулитом. Нефрология и диализ. 2017;19(4):466-477. doi:10.28996/1680-4422-2017-4-466-477

26. Mohammad AJ, Jacobsson LTH, Westman KWA et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology. 2009;48(12):1560-1565. doi:10.1093/rheumatology/kep304

27. cr.minzdrav.gov.ru [Internet]. Kлинические рекомен дации. Хроническая болезнь почек, 2024. Доступно по ссылке: https://cr.minzdrav.gov.ru/view-cr/469_3. Дата обращения 14 июня 2025.

28. Kallenberg CGM. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis. 2011;70(Suppl 1):i59-i63. doi:10.1136/ard.2010.138024

29. Novikov P, Smitienko I, Bulanov N et al. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases. Ann Rheum Dis. 2016;76(8):e23. doi:10.1136/annrheumdis-2016-210890

30. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;135(5):921-930.

31. Bosch X, Mirapeix E, Font J et al. Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis. Am J Kidney Dis. 1992;20(3):231-239. doi: 10.1016/s0272-6386(12)80695-0

32. Holle JU, Laudien M, Gross WL. Clinical Manifestations and Treatment of Wegener’s Granulomatosis. Rheumatic Disease Clinics of North America. 2010;36(3):507-526. doi:10.1016/j.rdc.2010.05.008

33. Villiger PM, Guillevin L. Microscopic polyangiitis: Clinical presentation. Autoimmun Rev. 2010;9(12):812-819. doi:10.1016/j.autrev.2010.07.009

34. Щеголева ЕМ, Буланов НМ, Новиков ПИ, Моисеев СВ. Клинические особенности поражения почек при микроскопическом полиангиите. Терапевтический архив. 2018; 90(6):55-58. doi: 10.26442/terarkh201890655-58

35. Guillevin L, Cohen P, Gayraud M et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine. 1999;78(1):26-37.

36. Буланов НМ, Моисеев СВ, Новиков ПИ и соавт. Поражение почек при различных вариантах АНЦА-ассоциированного васкулита. Клиническая фармакология и терапия. 2016;25(5):23-29. doi: 10.1097/00005792-199901000-00003

37. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum. 1990;33(8):1101-1107. doi:10.1002/ART.1780330807

38. Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of ChurgStrauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33(8):1094-1100. doi:10.1002/art.1780330806

39. Seeliger B, Sznajd J, Robson JC et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology (United Kingdom). 2017;56(7):1154-1161. doi:10.1093/rheumatology/kex075

40. Robson JC, Grayson PC, Ponte C et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315-320. doi:10.1136/ANNRHEUMDIS-2021-221795

41. Suppiah R, Robson JC, Grayson PC et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321-326. doi:10.1136/ANNRHEUMDIS-2021-221796

42. Grayson PC, Ponte C, Suppiah R et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis. 2022;81(3):309-314. doi:10.1136/ANNRHEUMDIS-2021-221794

43. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68(3):310-317. doi:10.1136/ard.2008.088096

44. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164-1177. doi:10.1046/j.1523-1755.2003.00843.x

45. Falk RJ, Moore DT, Hogan SL, Jennette JC. A renal biopsy in essential for the management of ANCA-positive patients with glomerulonephritis. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(3):230-231.

46. rusnephrology.org [Internet]. Клинические рекомендации. Острое повреждение почек. Доступно по ссылке: https://rusnephrology.org/wp-content/uploads/2020/12/AKI_final.pdf. Дата обращения 14 июня 2025.

47. Yu A, Chertow G, Luyckx V et al. Brenner and Rector’s The Kidney, 11th Ed. Publisher Elsevier. 2019. ISBN: 9780323532655

48. Deshayes S, Aouba A, Khoy K et al. Hypocomplementemia is associated with worse renal survival in anca-positive granulomatosis with polyangiitis and microscopic polyangiitis. PLoS One. 2018;13(4). doi:10.1371/journal.pone.0195680

49. Augusto JF, Langs V, Demiselle J et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PLoS One. 2016;11(7). doi:10.1371/journal.pone.0158871

50. Crnogorac M, Horvatic I, Kacinari P et al. Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome. J Nephrol. 2018;31(2):257-262. doi:10.1007/s40620-017-0445-3

51. Guchelaar NAD, Waling MM, Adhin AA et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmun Rev. 2021;20(1):102716. doi:10.1016/j.autrev.2020.102716

52. Bossuyt X, Cohen Tervaert JW, Arimura Y et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683-692. doi:10.1038/nrrheum.2017.140

53. Damoiseaux J, Csernok E, Rasmussen N et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigenspecific immunoassays. Ann Rheum Dis. 2017;76(4):647-653. doi:10.1136/annrheumdis-2016-209507

54. Savige J, Dimech W, Fritzler M et al. Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies: Quality Control Guidelines, Comments, and Recommendations for Testing in Other Autoimmune Diseases. Am J Clin Pathol. 2003;120(3):312-318. doi:10.1309/waep-adw0-k4lp-uhfn

55. Csernok E, Damoiseaux J, Rasmussen N et al. Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmun Rev. 2016;15(7):736-741. doi:10.1016/j.autrev.2016.03.010

56. Shah S, Hruskova Z, Segelmark M et al. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab. Am J Nephrol. 2015;41(4-5):296-301. doi:10.1159/000431336

57. Wester Trejo MAC, Floßmann O, Westman KW et al. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome. Rheumatology (Oxford). 2019;58(1):103-109. doi: 10.1093/rheumatology/key260

58. Chakravarty K, McDonald H, Pullar T et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology. 2008;47(6):924-925. doi:10.1093/rheumatology/kel216a

59. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44. doi:10.1056/NEJMoa020286

60. Talar-Williams C, Hijazi YM, Walther MM et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477-484. doi:10.7326/0003-4819-124-5-199603010-00003

61. Knight A, Askling J, Granath F et al. Urinary bladder cancer in Wegener’s granulomatosis: Risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63(10):1307-1311. doi:10.1136/ard.2003.019125

62. Stillwell TJ, Benson RC, Deremee RA et al. Cyclophosphamide-induced bladder toxicity in wegener’s granulomatosis. Arthritis Rheum. 1988;31(4):465-470. doi:10.1002/art.1780310402

63. Suppiah R, Mukhtyar C, Flossmann O et al. A crosssectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis. Rheumatology. 2011;50(5):899-905. doi:10.1093/rheumatology/keq400

64. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371-380. doi:10.1002/art.1780400222

65. Tomasson G, Grayson PC, Mahr AD et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology. 2012;51(1):100-109. doi:10.1093/rheumatology/ker280

66. Al-Soudi A, Vegting Y, Klarenbeek PL, Hilhorst ML. Do Relapses Follow ANCA Rises? A Systematic Review and MetaAnalysis on the Value of Serial ANCA Level Evaluation. Front Med (Lausanne). 2022;9. doi:10.3389/FMED.2022.844112,

67. Mehta P, Balakrishnan A, Phatak S et al. Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis. Rheumatol Int. 2023;43(3):437-448. doi:10.1007/S00296-022-05192-3,

68. Finkielman JD, Merkel PA, Schroeder D et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007;147(9):611-619.

69. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43(9):2025-2033. doi:10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O

70. Venhoff N, Effelsberg NM, Salzer U et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCAassociated vasculitides. PLoS One. 2012;7(5):e37626. doi:10.1371/journal.pone.0037626

71. Marco H, Smith RM, Jones RB et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord. 2014;15(1):178. doi:10.1186/1471-2474-15-178

72. Feragalli B, Mantini C, Sperandeo M et al. The lung in systemic vasculitis: Radiological patterns and differential diagnosis. British Journal of Radiology. 2016;89(1061):20150992. doi:10.1259/bjr.20150992

73. Zhou P, Ma J, Wang G. Impact of interstitial lung disease on mortality in ANCA-associated vasculitis: A systematic literature review and meta-analysis. Chron Respir Dis. 2021;15(8):1103-1111. doi:10.1177/1479973121994562

74. Huang S, Shen Q, Yang R et al. An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis. Int Urol Nephrol. 2018;50(10):1853-1861. doi:10.1007/s11255-018-1941-7

75. van Daalen EE, Wester Trejo MAC, Göçeroglu A et al. Developments in the histopathological classification of ANCAassociated glomerulonephritis. Clinical Journal of the American Society of Nephrology. 2020;15(8):1103-1111. doi:10.2215/CJN.14561119

76. Xia M, Yu R, Zheng Z et al. Meta-Analytical Accuracy of ANCA Renal Risk Score for Prediction of Renal Outcome in Patients With ANCA-Associated Glomerulonephritis. Front Med (Lausanne). 2022;8: 736754. doi:10.3389/FMED.2021.736754,

77. Aasarød K, Bostad L, Hammerstrøm J et al. Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrology Dialysis Transplantation. 2001;16(5):953-960. doi:10.1093/ndt/16.5.953

78. Schnabel A, Holl-Ulrich K, Dalhoff et al. Efficacy of transbronchial biopsy in pulmonary vaculitides. European Respiratory Journal. 1997;10(12):2738-2743. doi:10.1183/09031936.97.10122738

79. Devaney KO, Travis WD, Hoffman G et al. Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients. American Journal of Surgical Pathology. 1990;14(6):555-564. doi:10.1097/00000478-199006000-00006

80. Prasad N, Kumar S, Manjunath R et al. Real-time ultrasound-guided percutaneous renal biopsy with needle guide by nephrologists decreases post-biopsy complications. Clin Kidney J. 2015;8(2):151-156. doi:10.1093/ckj/sfv012

81. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21(10):1628-1636. doi:10.1681/ASN.2010050477

82. Brix SR, Noriega M, Tennstedt P et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 2018;94(6):1177-1188. doi:10.1016/j.kint.2018.07.020

83. Gercik O, Bilgin E, Solmaz D. Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis. 2020;79(5):675-676. doi:10.1136/annrheumdis-2019-216742

84. Bate S, McGovern D, Costigliolo F et al. The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials. Journal of the American Society of Nephrology. 2024;35(3):335-346. doi:10.1681/ASN.0000000000000274

85. Буланов НМ, Тао ЕА, Столяревич ЕС и соавт. Сравнение инструментов оценки прогноза почечной выживаемости у пациентов с АНЦА-ассоциированным гломерулонефритом: ретроспективное когортное исследование. 2024;33(4):44-50.doi:10.32756/0869-5490-2024-4-44-50

86. Добронравов ВА, Карунная АВ, Казимирчик АВ, Смирнов АВ. АНЦА-ассоциированные васкулиты с домини рующим поражением почек: клинико-морфологическая презентация и исходы. Нефрология. 2019;23(6):29-44. doi:10.36485/1561-6274-2019-236-29-44

87. Moosig F, Bremer JP, Hellmich B et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): Monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72(6):1011-1017. doi:10.1136/annrheumdis-2012-201531

88. Rovin BH, Adler SG, Barratt J et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi:10.1016/j.kint.2021.05.021

89. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827-1832. doi:10.1136/ard.2008.101279

90. Charlier C, Henegar C, Launay O et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis. 2009;68(5):658-663. doi:10.1136/ARD.2008.088302

91. Iudici M, Pagnoux C, Courvoisier DS et al. Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. Semin Arthritis Rheum. 2021;51(2):339-346. doi:10.1016/J.SEMARTHRIT.2021.02.002

92. Литвинова МА, Буланов НМ, Новиков ПИ и соавт. Коморбидные инфекции у пациентов с АНЦАассоциированными системными васкулитами: проспективное когортное исследование. Современная ревматология. 2025; 19(2):50-57.doi:10.14412/1996-7012-2025-2-50-57

93. Luo W, Liu C, Zhang L et al. Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis. Autoimmun Rev. 2025;24(2): 103713. doi:10.1016/j.autrev.2024.103713

94. Leong A, Fong W. Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: A narrative review. Int J Rheum Dis. 2022;25(12):1357-1367. doi:10.1111/1756-185X.14444

95. Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45(3):346-368. doi:10.1111/ECI.12410

96. Baliga S, Yadav S, Sagdeo P, Balakrishnan C. Invasive fungal infection in ANCA-associated vasculitis: Between the Devil and Deep blue sea. Case series and review of the literature. Clin Rheumatol. 2024;43(2):785-797. doi:10.1007/S10067-023-06785-4

97. Thery-Casari C, Euvrard R, Mainbourg S et al. Severe infections in patients with anti-neutrophil cytoplasmic antibodyassociated vasculitides receiving rituximab: A meta-analysis. Autoimmun Rev. 2020;19(5):102505. doi:10.1016/j.autrev.2020.102505

98. Shang W, Ning Y, Xu X et al. Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies. PLoS One. 2015;10(5):e0126016. doi:10.1371/JOURNAL.PONE.0126016

99. Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100-105.

100. Houben E, Penne EL, Voskuyl AE et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis of observational studies. Rheumatology (United Kingdom). 2018;57(3):555-562. doi:10.1093/rheumatology/kex338

101. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435. doi:10.1186/s13075-014-0435-y

102. Goyal A, Abbasi HQ, Mashkoor Y et al. Assessment of cardiovascular risk in patients with ANCA-associated vasculitis: A systematic review and meta-analysis. International Journal of Cardiology: Cardiovascular Risk and Prevention. 2024;23:200334. doi:10.1016/j.ijcrp.2024.200334

103. Suppiah R, Judge A, Batra R et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63(4):588-596. doi:10.1002/acr.20433

104. Макаров ЕА, Новиков ПИ, Шевцова ТП и соавт. Венозные тромбоэмболические осложнения при АНЦАассоциированных васкулитах. Клиническая фармакология и терапия. 2017;26(3):37-42.

105. Moiseev S, Kronbichler A, Makarov E et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology. 2021;60(10):4654-4661. doi:10.1093/rheumatology/keab071

106. Moiseev S, Novikov P, Bulanov N et al. Cardiovascular risk assessment in patients with ANCA-associated vasculitis. Arthritis & Rheumatology. 2020;72(1):200-201. doi:10.1002/art.41080

107. Кузнецова ЕИ, Моисеев СВ, Новиков ПИ и соавт. Субклинический атеросклероз периферических артерий у больных гранулематозом с полиангиитом (Вегенера). Клиническая фармакология и терапия. 2013;22(4):36-41.

108. Wallace ZS, Fu X, Liao K et al. Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol. 2019;71(11):1879-1887. doi:10.1002/art.41006

109. Moiseev S, Bulanov N, Crnogorac M et al. Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multinational Retrospective Study. Journal of Rheumatology. 2023;50(9):1145-1151. doi:10.3899/JRHEUM.220851,

110. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis). Br Med J. 1958;2(5091):265-270.

111. de Groot K, Adu D, Savage CO et al. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16(10):2018-2027. doi:10.1093/ndt/16.10.2018

112. de Groot K, Harper L, Jayne DRW et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-680. doi:10.7326/0003-4819-150-10-200905190-00004

113. Hoffman GS, Kerr GS, Leavitt RY et al. Wegener Granulomatosis: An Analysis of 158 Patients. Ann Intern Med. 1992;116(6):488. doi:10.7326/0003-4819-116-6-488

114. Novack SN, Pearson CM. Cyclophosphamide Therapy in Wegener’s Granulomatosis. New England Journal of Medicine. 1971;284(17):938-942. doi:10.1056/NEJM197104292841703

115. Ntatsaki E, Carruthers D, Chakravarty K et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (United Kingdom). 2014;53(12):2306-2309. doi:10.1093/rheumatology/ket445

116. Bender TTA, Leyens J, Sellin J et al. Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15(1):308. doi:10.1186/s13023-020-01576-5

117. Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, and cyclophosphamide in active antineutrophil cytoplasmic antibodyassociated vasculitis: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2021;59(10):645-653. doi:10.5414/CP204024,

118. Jones RB, Tervaert JWC, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi:10.1056/NEJMoa0909169

119. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi:10.1056/NEJMoa0909905

120. Caroti L, Cirami CL, Di Maria L et al. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: A case series. BMC Nephrol. 2019;20(1):162. doi:10.1186/s12882-019-1350-x

121. Walsh M, Merkel P, Peh C et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med. 2020;382:622-631. doi:10.1056/NEJMoa1803537

122. Alchi MB, Lever R, Flossmann O, Jayne D. Efficacy and safety of low- versus high-dose glucocorticoid regimens for induction of remission of anti-neutrophil cytoplasm antibodyassociated vasculitis: a systematic review and meta-analysis. Scand J Rheumatol. 2023;52(5):564-573. doi:10.1080/03009742.2023.2211387,

123. Furuta S, Nakagomi D, Kobayashi Y et al. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. JAMA. 2021;325(21):1-10. doi:10.1001/JAMA.2021.6615

124. Jayne DRW, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-2188. doi:10.1681/ASN.2007010090

125. Yates M, Watts RA, Bajema IM et al. EULAR/ERAEDTA recommendations for the management of ANCAassociated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. doi:10.1136/annrheumdis-2016-209133

126. Guillevin L, Pagnoux C, Karras A et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-1780. doi:10.1056/NEJMoa1404231

127. Chanouzas D, McGregor JAG, Nightingale P et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: A multi-center retrospective cohort study 11 Medical and Health Sciences 1103 Clinical Sciences. BMC Nephrol. 2019;20(1):58. doi:10.1186/s12882-019-1226-0

128. Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384(7):599-609. doi:10.1056/NEJMOA2023386

129. Gattu R, Demory Beckler M, Kesselman MM. Superiority of Avacopan and Mepolizumab to Glucocorticoid Tapering in the Treatment of Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review. Cureus. 2024;16(8):e67161. doi:10.7759/CUREUS.67161

130. Cortazar FB, Niles JL, Jayne DRW et al. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. Kidney Int Rep. 2023;8(4):860-870. doi:10.1016/j.ekir.2023.01.039

131. Geetha D, Dua A, Yue H et al. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann Rheum Dis. 2023;83(2):223-232. doi:10.1136/ARD-2023-224816,

132. Miloslavsky EM, Naden RP, Bijlsma JWJ et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543-546. doi:10.1136/ANNRHEUMDIS-2016-210002

133. Zonozi R, Aqeel F, Le D et al. Real-World Experience With Avacopan in Antineutrophil Cytoplasmic AutoantibodyAssociated Vasculitis. Kidney Int Rep. 2024;9(6):1783-1791. doi:10.1016/J.EKIR.2024.03.022,

134. Chalkia A, Flossmann O, Jones R et al. Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. Nephrology Dialysis Transplantation. 2024;39(9):1473-1482. doi:10.1093/NDT/GFAE020,

135. Merkel PA, Niles J, Jimenez R et al. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. ACR Open Rheumatol. 2020;2(11):662-671. doi:10.1002/ACR2.11185,

136. Jayne DRW, Bruchfeld AN, Harper L et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. Journal of the American Society of Nephrology. 2017;28(9):2756-2767. doi:10.1681/ASN.2016111179,

137. Cortazar FB, Muhsin SA, Pendergraft WF et al. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney Int Rep. 2018;3(2):394-402. doi:10.1016/j.ekir.2017.11.004

138. Pepper RJ, McAdoo SP, Moran SM et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2019;58(2):260-268. doi:10.1093/rheumatology/key288

139. Xiong A, Xiong C, Yang G et al. The Role of Mycophenolate Mofetil for the Induction of Remission in ANCAAssociated Vasculitis: A Meta-Analysis. Front Med (Lausanne). 2021;8:609924. doi:10.3389/fmed.2021.609924

140. Kuzuya K, Morita T, Kumanogoh A. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: Associated vasculitis - A meta-analysis. RMD Open. 2020;6(1):e001195. doi:10.1136/rmdopen-2020-001195

141. Berti A, Alsawas M, Jawaid T et al. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrol Dial Transplant. 2022;37(11):2190-2200. doi:10.1093/NDT/GFAB357,

142. Hu W, Liu C, Xie H et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008;23(4):1307-1312. doi:10.1093/ndt/gfm780

143. Han F, Liu G, Zhang X et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol. 2011;33(2):185-192. doi: 10.1159/000324364

144. Tuin J, Stassen PM, Bogdan DI et al. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Clinical Journal of the American Society of Nephrology. 2019;14(7):1021-1028. doi:10.2215/cjn.11801018

145. Jones RB, Hiemstra TF, Ballarin J et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399-405. doi:10.1136/annrheumdis-2018-214245

146. Yamada Y, Harada M, Hara Y et al. Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis. Arthritis Res Ther. 2021;23(1):28. doi:10.1186/s13075-021-02415-z

147. Walsh M, Collister D, Zeng L et al. The effects of plasma exchange in patients with ANCA-Associated vasculitis: An updated systematic review and meta-Analysis. The BMJ. 2022;376:e064604. doi:10.1136/BMJ-2021-064604,

148. Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosisa clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26(1):206-213. doi:10.1093/ndt/gfq360

149. Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757-763. doi:10.1038/ki.1991.272

150. Levy JB, Hammad T, Coulthart A et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66(4):1535-1540. doi:10.1111/j.1523-1755.2004.00917.x

151. Puéchal X, Pagnoux C, Baron G et al. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. Arthritis Rheumatol. 2017;69(11):2175-2186. doi:10.1002/art.40205

152. Lionaki S, Hogan SL, Jennette CE et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009;76(6):644-651. doi:10.1038/ki.2009.218

153. Geetha D, Jefferson JA. ANCA-Associated Vasculitis: Core Curriculum 2020. Am J Kidney Dis. 2020;75(1):124–137. doi:10.1053/j.ajkd.2019.04.031

154. Lee YH, Song GG. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network metaanalysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022;60(2):97-105. doi:10.5414/CP204053

155. Charles P, Terrier B, Perrodeau É et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1144-1150. doi:10.1136/annrheumdis-2017-212878

156. Delestre F, Charles P, Karras A et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: Pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2023;83(2):233-241. doi:10.1136/ARD-2023-224623,

157. Smith RM, Jones RB, Specks U et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis. 2020;79(9):1243-1249. doi:10.1136/annrheumdis-2019-216863

158. Pagnoux C, Mahr A, Hamidou M et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790-2803. doi:10.1056/NEJMc090138

159. Hiemstra TF, Walsh M, Mahr A et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381-2388. doi:10.1001/jama.2010.1658

160. He P, Hu JP, Tian XJ et al. Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies. Rheumatology. 2021;60(3):1067-1079. doi:10.1093/rheumatology/keaa667

161. Weidanz F, Day CJ, Hewins P et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis. 2007;50(1):36-46. doi:10.1053/j.ajkd.2007.04.018

162. Chen M, Zhao MH. Severe pulmonary hemorrhage in patients with end-stage renal disease in antineutrophil cytoplasmic autoantibody-associated vasculitis. Am J Med Sci. 2009;337(6):411-414. doi:10.1097/MAJ.0b013e3181928d24

163. Springer J, Nutter B, Langford CA et al. Granulomatosis with polyangiitis (Wegener’s): Impact of maintenance therapy duration. Medicine (United States). 2014;93(2):82-90. doi:10.1097/MD.0000000000000020

164. Karras A, Pagnoux C, Haubitz M et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662-1668. doi:10.1136/annrheumdis-2017-211123

165. Charles P, Perrodeau É, Samson M et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med. 2020;173(3):179-187. doi:10.7326/M19-3827

166. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken). 2010;62(8):1166-1173. doi:10.1002/acr.20176

167. Pagnoux C, Quéméneur T, Ninet J et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: Results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheum. 2015;67(4):1117-1127. doi:10.1002/art.39011

168. Faurschou M, Sorensen IJ, Mellemkjaer L et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100-105.

169. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605-617. doi:10.1136/ard.2006.062711

170. Cartin-Ceba R, Keogh KA, Specks U et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrology Dialysis Transplantation. 2011;26(9):2865-2871. doi:10.1093/ndt/gfq852

171. Pullerits R, Ljevak M, Vikgren J, Bokarewa M. Off-Trial Evaluation of the B cell-Targeting Treatment in the Refractory Cases of Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis: Long-Term Follow-Up from a Single Centre. Scand J Immunol. 2012;76(4):411-420. doi:10.1111/j.1365-3083.2012.02747.x

172. Miloslavsky EM, Specks U, Merkel PA et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2013;65(9):2441-2449. doi:10.1002/art.38044

173. Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology (United Kingdom). 2020;59(5):959-967. doi:10.1093/rheumatology/kez311

174. Fortin PM, Tejani AM, Bassett K, Musini VM. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database of Syst Rev. 2013;3:CD0070057. doi:10.1002/14651858.CD007057.pub3

175. Muso E, Ito-Ihara T, Ono T et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis. 2004;57(5):S17-18.

176. Jayne DRW. Intravenous immunoglobulin for ANCAassociated systemic vasculitis with persistent disease activity. QJM. 2000;93(7):433-439. doi:10.1093/qjmed/93.7.433

177. O’Shaughnessy MM, Liu S, Montez-Rath ME et al. Kidney transplantation outcomes across GN subtypes in the United States. Journal of the American Society of Nephrology. 2017;28(2):632-644. doi:10.1681/ASN.2016020126

178. Geetha D, Eirin A, True K et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience. Transplantation. 2011;91(12):1370-1375. doi:10.1097/TP.0b013e31821ab9aa

179. Little MA, Hassan B, Jacques S et al. Renal transplantation in systemic vasculitis: When is it safe. Nephrol Dial Transplant. 2009;24(10):3219-3225. doi:10.1093/ndt/gfp347

180. Marco H, Mirapeix E, Arcos E et al. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. Clin Transplant. 2013;27(3):338-347. doi:10.1111/ctr.12084

181. Stern A, Green H, Paul M et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;(10):CD005590. doi:10.1002/14651858.CD005590.pub3

182. Kronbichler A, Kerschbaum J, Gopaluni S et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/lifethreatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440-1147. doi:10.1136/annrheumdis-2017-212861

183. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology. 2001;40(5):492-498. doi:10.1093/rheumatology/40.5.492

184. Bligny D, Mahr A, Toumelin P et al. Predicting mortality in systemic Wegener’s granulomatosis: A survival analysis based on 93 patients. Arthritis Care Res (Hoboken). 2004;51(1):83-91. doi:10.1002/art.20082

185. Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45(3):346-368. doi:10.1111/eci.12410

186. Furer V, Rondaan C, Heijstek MW et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi:10.1136/annrheumdis-2019-215882

187. Groh M, Puéchal X, Terrier B et al. Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study. Joint Bone Spine. 2017;84(5):643-644. doi:10.1016/j.jbspin.2016.09.019

188. Stassen PM, Sanders JSF, Kallenberg CGM, Stegeman CA. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrology Dialysis Transplantation. 2008;23(2):654-658. doi:10.1093/ndt/gfm640

189. Jeffs LS, Peh CA, Jose MD et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology. 2015;20(5):343-351. doi:10.1111/nep.12416

190. Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021-1032. doi:10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J

191. Fredi M, Lazzaroni MG, Tani C et al. Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmun Rev. 2015;14(8):686-691. doi:10.1016/j.autrev.2015.03.009

192. Veltri NL, Hladunewich M, Bhasin A et al. De novo antineutrophil cytoplasmic antibody-associated vasculitis in pregnancy: a systematic review on maternal, pregnancy and fetal outcomes. Clin Kidney J. 2018;11(5):659-666. doi:10.1093/ckj/sfy011

193. Leroy C, Rigot JM, Leroy M et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136. doi:10.1186/s13023-015-0332-8

194. Rüegg L, Pluma A, Hamroun S et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910-926. doi:10.1016/J.ARD.2025.02.023

195. Langford CA. Update on Wegener granulomatosis. Cleve Clin J Med. 2005;72(8):689-697. doi:10.3949/ccjm.72.8.689

196. Seo P, Min YI, Holbrook JT et al. Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2005;52(7):2168-2178. doi:10.1002/art.21117

197. Flossmann O, Berden A, De Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488-494. doi:10.1136/ard.2010.137778

198. Basu N, Mcclean A, Harper L et al. Explaining fatigue in ANCA-associated vasculitis. Rheumatology (United Kingdom). 2013;52(9):1680-1685. doi:10.1093/rheumatology/ket191

199. O’Malley L, Druce K, Chanouzas D et al. The Longitudinal Course of Fatigue in Anca Associated Vasculitis. J Rheumatol. 2020;47(4):572-579. doi:10.3899/jrheum.190113

200. Basu N, Mcclean A, Harper L et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (United Kingdom). 2014;53(5):953-956. doi:10.1093/rheumatology/ket483

201. Yun J Di, Ha J, Kim S et al. Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibodyassociated vasculitis. Clin Rheumatol. 2019;38(12):3485-3491. doi:10.1007/s10067-019-04657-4

202. Basu N, McClean A, Harper L et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis. 2014;73(1):207-211. doi:10.1136/annrheumdis-2012-202750

203. Herlyn K, Gross WL, Reinhold-Keller E. Longitudinal effects of structured patient education programs for vasculitis patients. Z Rheumatol. 2008;67(3):206-210. doi:10.1007/s00393-008-0290-9 (In German)

204. Pagnoux C, Hogan SL, Chin H et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58(9):2908-2918. doi:10.1002/art.23800

205. Lionaki S, Blyth ER, Hogan SL et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452-3462. doi:10.1002/art.34562

206. Holle JU, Gross WL, Latza U et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 2011;63(1):257-266. doi:10.1002/art.27763

207. de Lind van Wijngaarden RAF, Hauer HA, Wolterbeek R et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17(8):2264-2274. doi:10.1681/ASN.2005080870

208. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67(7):1004-1010. doi:10.1136/ard.2007.071936

209. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488-494. doi:10.1136/ard.2010.137778

210. Hogan SL, Nachman PH, Wilkman AS et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibodyassociated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):23-32. doi: 10.1681/ASN.V7123

211. Семенкова ЕН, Кривошеев ОГ, Новиков ПИ. Поражение легких при гранулематозе Вегенера. Клиническая медицина. 2011;1:10-13.